Logo
x

Search

Subscribe Now

Commercialization Agreement

Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

  • July 13, 2021
Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201 (biosimilar- ranibizumab)

  • June 29, 2021
Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to S...

  • April 9, 2021
Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio

Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio

  • November 7, 2019
STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven Biosimilars in Europe

  • November 7, 2019
Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar- teriparatide)

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies for PF708 (biosimilar- teriparatide)

  • October 23, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.